Shanghai-based Antengene has ushered in the first biotech mega-round of the year, designed to fuel a quick commercial turnaround of in-licensed cancer drugs.
The $120 million Series B marks a significant boost for the young biotech, which was founded in April 2017 on a deal with Celgene $CELG, and quite possibly the last financing round before Antengene heads to an IPO — according to previous comments by CEO Jay Mei.
Boyu Capital led the round alongside FountainVest, with help from Series A leader Qiming Venture Partners, founding investor Celgene, as well as WuXi Corporate Venture Fund and Taikang.
“We view in-licensing of first-in-class/best-in-class drug candidates as an effective solution to the unmet clinical needs in China,” said Boyu managing director Yanling Cao in a statement. “In addition, we are very impressed with the progress that Antengene is making and the pipeline they are building.”
Aside from Celgene’s TORC1/2 inhibitor — now dubbed ATG008 — Antengene’s pipeline includes another lead program in-licensed from Karyopharm in a partnership that covered three other early-stage assets. ATG-010, or selinexor, is in Phase III trials for multiple myeloma and liposarcoma.
While the cash infusion will go a long way in funding the later-stage development of these assets, further beefing up the company’s pipeline and preparing for a potential commercial launch, an IPO — with a 50/50 chance of falling in the US and Hong Kong — could be looming in the next 12 months.
“We need to be ready,” Mei told a group of reporters at the BIIS conference organized by Endpoints News and PharmCube last October. “The market doesn’t wait for companies. Companies must catch market opportunities.”
Antengene is also building a 160,000-plus square feet manufacturing site in Shaoxing, China to supply its own clinical and commercial drugs.
Image: Jay Mei at the Biopharma Innovation and Investment Summit 2018. ENDPOINTS NEWS, PHARMCUBE
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.Free Subscription